---
reference_id: "PMID:31498767"
title: "ACE inhibitors and ARBs: Managing potassium and renal function."
authors:
- Momoniat T
- Ilyas D
- Bhandari S
journal: Cleve Clin J Med
year: '2019'
doi: 10.3949/ccjm.86a.18024
content_type: abstract_only
---

# ACE inhibitors and ARBs: Managing potassium and renal function.
**Authors:** Momoniat T, Ilyas D, Bhandari S
**Journal:** Cleve Clin J Med (2019)
**DOI:** [10.3949/ccjm.86a.18024](https://doi.org/10.3949/ccjm.86a.18024)

## Content

1. Cleve Clin J Med. 2019 Sep;86(9):601-607. doi: 10.3949/ccjm.86a.18024.

ACE inhibitors and ARBs: Managing potassium and renal function.

Momoniat T(1), Ilyas D(1), Bhandari S(2).

Author information:
(1)Department of Nephrology, Hull University Teaching Hospitals NHS Trust, East 
Yorkshire, United Kingdom.
(2)Department of Nephrology, Hull Royal Infirmary, Hull University Teaching 
Hospitals NHS Trust, East Yorkshire, United Kingdom. Sunil.Bhandari@hey.nhs.uk.

Comment in
    Cleve Clin J Med. 2019 Sep;86(9):608-611. doi: 10.3949/ccjm.86a.19016.
    Cleve Clin J Med. 2020 Jan;87(1):9. doi: 10.3949/ccjm.87c.01001.

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor 
blockers (ARBs) are used primarily to treat hypertension and are also useful for 
conditions such as heart failure and chronic kidney disease, independent of 
their effect on blood pressure. This article reviews the indications for ACE 
inhibitors and ARBs and offers advice for managing their adverse effects, 
particularly declining renal function and hyperkalemia.

Copyright Â© 2019 Cleveland Clinic.

DOI: 10.3949/ccjm.86a.18024
PMID: 31498767 [Indexed for MEDLINE]